Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 6: 830 - 833

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.06.022

Review

Expression and significance of ATP-binding cassette superfamily G member 2 in lung cancer

  • Jian-hua XU ,
  • Ping JIANG ,
  • Jiong DENG
Expand
  • 1.Department of Pathology and Pathophysiology, Kunming Medical University, Kunming 650032, China
    2.Key laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China

Online published: 2021-06-29

Supported by

National Natural Science Foundation of China(81620108022)

Fold

Abstract

The stemness and drug resistance of lung cancer cells are important features of malignancy. ATP-binding cassette superfamily G member 2 (ABCG2), a member of the ATP-binding cassette transporter family, is localized in the membrane of a variety of human cancer cells and excludes drugs from cells in an ATP-dependent manner. Single nucleotide polymorphisms in ABCG2 gene are significantly associated with multidrug resistance in cancer chemotherapy. In addition, ABCG2 has been used as a supporting biomarker for the identification of lung cancer stem cells. This review summarizes recent research progress in ABCG2, focusing on the regulation of ABCG2 gene expression, the potential roles of ABCG2 on cancer cell stemness, and the correlation of single nucleotide polymorphisms in ABCG2 with drug resistance in lung cancer, in order to provide a new strategy for the clinical treatment of lung cancer patients.

Key words： ATP-binding cassette superfamily G member 2 (ABCG2); lung cancer; stemness; drug resistance

Cite this article

Jian-hua XU , Ping JIANG , Jiong DENG . Expression and significance of ATP-binding cassette superfamily G member 2 in lung cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(6) : 830 -833 . DOI: 10.3969/j.issn.1674-8115.2021.06.022

References

1 Ke B, Wei T, Huang Y, et al. Interleukin-7 resensitizes non-small-cell lung cancer to cisplatin via inhibition of ABCG2[J]. Mediators Inflamm, 2019, 2019: 7241418.
2 Kovacsics D, Brózik A, Tihanyi B, et al. Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells[J]. Biochem Pharmacol, 2020, 175: 113865.
3 Barton MK. Adjuvant chemotherapy benefits older and younger non-small cell lung cancer patients alike[J]. CA Cancer J Clin, 2012, 62(5): 279-280.
4 Ke SZ, Ni XY, Zhang YH, et al. Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-κB pathway in lung cancer cells[J]. Int J Oncol, 2013, 42(4): 1289-1296.
5 Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy[J]. Life Sci, 2010, 86(17/18): 631-637.
6 Monzo M, Rosell R, Taron M. Drug resistance in non-small cell lung cancer[J]. Lung Cancer, 2001, 34: S91-S94.
7 Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer[J]. Clin Cancer Res, 2004, 10(5): 1691-1697.
8 Doyle LA, Yang WD, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci USA, 1998, 95(26): 15665-15670.
9 Chen LM, Manautou JE, Rasmussen TP, et al. Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2[J]. Acta Pharm Sin B, 2019, 9(4): 659-674.
10 Lusvarghi S, Robey RW, Gottesman MM, et al. Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models[J]. F1000Res, 2020, 9 (F1000 Faculty Rev): 17.
11 Dai YY, Liu S, Zhang WQ, et al. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells[J]. Oncotarget, 2017, 8(3): 4096-4109.
12 Hu CF, Huang YY, Wang YJ, et al. Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells[J]. Oncol Rep, 2016, 36(1): 455-461.
13 Wang Q, Geng F, Zhou H, et al. MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β-catenin signaling pathway[J]. Oncol Lett, 2019, 18(4): 4294-4307.
14 Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype[J]. Nat Med, 2001, 7(9): 1028-1034.
15 Yang B, Ma YF, Liu Y. Elevated expression of Nrf-2 and ABCG2 involved in multidrug resistance of lung cancer SP cells[J]. Drug Res (Stuttg), 2015, 65(10): 526-531.
16 Singh A, Wu HL, Zhang P, et al. Expression of ABCG2 (BCRP) is regulated by Nrf-2 in cancer cells that confers side population and chemoresistance phenotype[J]. Mol Cancer Ther, 2010, 9(8): 2365-2376.
17 Summer R, Kotton DN, Sun X, et al. Side population cells and Bcrp1 expression in lung[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 285(1): L97-L104.
18 Zhao WS, Luo Y, Li BY, et al. Tumorigenic lung tumorospheres exhibit stem-like features with significantly increased expression of CD133 and ABCG2[J]. Mol Med Rep, 2016, 14(3): 2598-2606.
19 Phiboonchaiyanan PP, Kiratipaiboon C, Chanvorachote P. Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism[J]. Chem Biol Interact, 2016, 250: 1-11.
20 Wei HY, Liang F, Cheng W, et al. The mechanisms for lung cancer risk of PM2.5: induction of epithelial-mesenchymal transition and cancer stem cell properties in human non-small cell lung cancer cells[J]. Environ Toxicol, 2017, 32(11): 2341-2351.
21 Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells[J]. Am J Physiol Cell Physiol, 2016, 310(9): C728-C739.
22 Miranda-Lorenzo I, Dorado J, Lonardo E, et al. Intracellular autofluorescence: a biomarker for epithelial cancer stem cells[J]. Nat Methods, 2014, 11(11): 1161-1169.
23 Cui JJ, Wang LY, Zhu T, et al. Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients[J]. Sci Rep, 2017, 7(1): 5082.
24 Campa D, Müller P, Edler L, et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis[J]. Int J Cancer, 2012, 131(12): 2920-2928.
25 Chen XQ, Chen DD, Yang SY, et al. Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients[J]. Cancer Cell Int, 2015, 15: 43.
26 Limviphuvadh V, Tan CS, Konishi F, et al. Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy[J]. BMC Cancer, 2018, 18(1): 555.
27 To KK, Poon DC, Wei YM, et al. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer[J]. Br J Pharmacol, 2015, 172(16): 4089-4106.
28 Galetti M, Petronini PG, Fumarola C, et al. Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines[J]. PLoS One, 2015, 10(11): e0141795.
29 Zhang GN, Zhang YK, Wang YJ, et al. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: in vitro and in vivo[J]. Cancer Lett, 2018, 424: 19-29.
30 Zhang W, Fan YF, Cai CY, et al. Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells[J]. Front Pharmacol, 2018, 9: 1097.
31 Bessho Y, Oguri T, Achiwa H, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer[J]. Cancer Sci, 2006, 97(3): 192-198.
32 Fujita H, Nagakawa K, Kobuchi H, et al. Phytoestrogen suppresses efflux of the diagnostic marker protoporphyrin Ⅸ in lung carcinoma[J]. Cancer Res, 2016, 76(7): 1837-1846.
33 Usuda J, Tsunoda Y, Ichinose S, et al. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer[J]. Lung Cancer, 2010, 67(2): 198-204.
34 Kort A, Sparidans RW, Wagenaar E, et al. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)[J]. Pharmacol Res, 2015, 102: 200-207.
35 Tang SC, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar[J]. Int J Cancer, 2014, 134(6): 1484-1494.
36 Zhang YM, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/P-gp[J]. Neoplasia, 2009, 11(1): 96-101.
37 Zhang W, Chen Z, Chen LK, et al. ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics[J]. Sci Rep, 2017, 7: 40064.
38 Westover D, Ling X, Lam H, et al. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance[J]. Mol Cancer, 2015, 14: 92.
Options
Outlines

/

〈 〉